Pencil Banner Copy AUGUST2023

Elevar Therapeutics and Jiangsu Hengrui Pharma announce global commercialization licensing agreement for camrelizumab LEARN MORE HERE
Title Image

Publications

Cancer Chemotherapy and Pharmacology 2023:  Comparative biochemical kinase activity analysis identifies rivoceranib as a highly selective VEGFR2 inhibitor.

ASCO 2023 Poster:  Updated results from a phase 2 study of the oral vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor rivoceranib for recurrent or metastatic (R/M) adenoid cystic carcinoma (ACC).

ASCO 2023: Updated results from a phase 2 study of the oral vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor rivoceranib for recurrent or metastatic (R/M) adenoid cystic carcinoma (ACC).

ASCO 2023:  Phase 1, randomized, open-label, single-dose, crossover study to evaluate the bioequivalence of four formulations of oral rivoceranib tablets in healthy subjects.

AACR 2023: Comparative Biochemical Kinase Activity Analysis Identifies Rivoceranib as a Highly Selective VEGFR-2 Inhibitor

AACR 2023: Effect of Rivoceranib on the Pharmacokinetics of Cytochrome P450 Enzyme Substrates: A Phase 1 Trial in Healthy Volunteers

ESMO 2022: Phase 1 Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of Rivoceranib Plus Paclitaxel in Advanced Gastric or Gastroesophageal Junction Cancer

ASCO 2022: A Phase 2 Study of the Oral Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) Inhibitor, Rivoceranib, for Recurrent or Metastatic (R/M) Adenoid Cystic Carcinoma (ACC)

Gynecologic Oncology: Phase 3 Publication of Efficacy & Safety Results Comparing Paclitaxel Micellar & Cremophor EL-Paclitaxel

ASCO Annual Meeting 2020 Poster Report of Rivoceranib in Recurrent or Metastatic Adenoid Cystic Carcinoma

ASCO-SITC Clinical Immuno-Oncology Symposium 2019 Poster Report of Rivoceranib in Combination with Nivolumab

AACR 2018 Poster Report of Preclinical Rivoceranib (Apatinib) Combination with Immunotherapy

ACCP 2017 Poster of a Phase 1 Ethnic PK Study

ASCO 2017 Poster Report of Apatinib Phase III Trial in Progress

ESMO 2016 Poster Report of Apatinib Phase II Study Results